2015
S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC).
Leichman C, McDonough S, Smalley S, Billingsley K, Lenz H, Beldner M, Hezel A, Velasco M, Guthrie K, Blanke C, Hochster H. S0713: A phase II study of cetuximab (CET) added to induction chemotherapy (ICT) of oxaliplatin (OX) and capecitabine (CAP), followed by neoadjuvant chemoradiation (NACR) for locally advanced rectal cancer (LARC). Journal Of Clinical Oncology 2015, 33: 3516-3516. DOI: 10.1200/jco.2015.33.15_suppl.3516.Peer-Reviewed Original Research
2009
Effect of Chemoradiation on Survival of Resected Pancreatic Ductal Adenocarcinoma with Close or Positive Margins
Bicquart C, Youssef R, Sheppard B, Corless C, Billingsley K, Thomas C. Effect of Chemoradiation on Survival of Resected Pancreatic Ductal Adenocarcinoma with Close or Positive Margins. International Journal Of Radiation Oncology • Biology • Physics 2009, 75: s291-s292. DOI: 10.1016/j.ijrobp.2009.07.671.Peer-Reviewed Original Research